

RESEARCH

Open Access



Mortality in individuals with childhood ADHD or subthreshold symptoms – a prospective perinatal risk cohort study over 40 years

Nella Schiavone^{1*}, Maarit Virta¹, Sami Leppämäki², Jyrki Launes¹, Ritva Vanninen³, Annamari Tuulio-Henriksson¹, Ilkka Järvinen¹, Eliisa Lehto¹, Katarina Michelsson⁴ and Laura Hokkanen¹

Abstract

Background: Attention-deficit/hyperactivity disorder (ADHD) is associated with negative life outcomes and recent studies have linked it to increased mortality. These studies have examined nationwide registers or clinic-referred samples and mostly included participants up until the age of 30. No studies have investigated mortality associated with subthreshold levels of ADHD symptoms. Our aim was to analyze mortality in a perinatal risk cohort of 46-year-old adults with childhood ADHD (cADHD) and milder childhood attention problems (including hyperactivity and inattention; cAP) compared with a group with similar birth risks but no or low levels of childhood ADHD symptoms (Non-cAP). Causes of death obtained from a national register were examined.

Methods: Mortality was analyzed with Cox proportional hazard models for all-cause mortality, cause-specific mortality (natural and unnatural causes), and age-specific mortality (under and over age 30). All models were adjusted with gender. The total *n* in the study was 839 (cADHD *n* = 115; cAP *n* = 216; Non-cAP *n* = 508).

Results: By the age of 46, 11 (9.6%) deaths occurred in the cADHD group, 7 (3.2%) in the cAP group, and 20 (3.9%) in the Non-cAP group. The cADHD group had the highest mortality risk (adjusted hazard ratio = 2.15; 95% CI 1.02, 4.54). Mortality was not elevated in the cAP group (adjusted hazard ratio = 0.72; 95% CI .30, 1.72). Mortality in the cADHD group was mainly attributed to unnatural causes of death (adjusted hazard ratio = 2.82; 95% CI 1.12, 7.12). The mortality risk in the cADHD group was sixfold before age 30 (adjusted hazard ratio = 6.20; 95% CI 1.78, 21.57).

Conclusions: Childhood ADHD was associated with a twofold risk of premature death by the age of 46 in this prospective longitudinal cohort study. Our results corroborate previous findings and the morbidity of ADHD. Subthreshold levels of childhood ADHD symptoms were not linked to increased mortality. Our results suggest that mortality risk is higher in young than middle adulthood. Future studies should examine mortality associated with ADHD in different ages in adulthood to identify those in greatest risk of premature death.

Keywords: ADHD, Subthreshold ADHD, Adult, Mortality, Cohort, Perinatal risk

Background

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder affecting 3%–5% of children [1] and approximately 2.8% of adults [2]. ADHD is associated with several impairing life outcomes,

*Correspondence: nella.schiavone@helsinki.fi

¹ Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finland

Full list of author information is available at the end of the article



including higher rates of incarceration, suicide attempts, drug abuse, and comorbid psychiatric disorders [1, 3–5].

The association of ADHD and increased mortality has gained more research focus in recent years. Studies on this association are yet few and have mainly been large nationwide studies (Table 1). These studies have discovered an association between ADHD and increased mortality based on an ADHD diagnosis retrieved from national registers [6–8] and self-reports [9]. Others have shown ADHD to be associated with reduced life expectancy based on both register data and a longitudinally followed sample [10, 11]. Studies examining ADHD-medicated individuals have found no association with increased mortality, which might be due to a small sample or a short follow-up period [12, 13]. A recent population-based cohort study observed a lower mortality risk associated with methylphenidate use in children and adolescents with ADHD [14]. Longitudinal prospective cohort studies examining mortality of individuals with ADHD are rare. A large cohort study found externalizing symptoms including aggression and impulsivity in childhood to be associated with increased mortality risk by the age of 46 [15]. In a population-based sample study with a mean follow-up age of 27, all-cause-mortality in individuals with ADHD was not increased compared to controls [16]. Another study following clinic-referred males with ADHD to an average age of 41 showed a significant difference in death rates between the ADHD and comparison groups [4].

Increased mortality associated with ADHD appears to be attributed to unnatural causes. In register studies accidents, suicides, and homicides have been the main causes of death in individuals with ADHD [6–8]. Cause-specific mortality for suicide was significantly higher for those with ADHD compared to controls in a longitudinal setting [16]. ADHD is not only associated with a higher risk of suicide but also suicidal behaviors [5, 17]. Mortality in individuals with ADHD is further increased by comorbid psychiatric disorders, especially substance use disorder, oppositional defiant disorder, and conduct disorder [6, 8].

ADHD symptoms follow a continuum and might fluctuate at different times during development causing an individual to reach a diagnostic threshold at one point in time but not at another [18–20]. ADHD symptoms that remain below the diagnostic threshold have attracted increasing interest in recent years. These subclinical symptoms, or subthreshold ADHD, have been linked to similar negative life outcomes as the full disorder, such as academic deficits and psychiatric comorbidity [19, 21, 22]. To the best of our knowledge, no studies have examined mortality associated with ADHD symptoms below the diagnostic threshold.

We investigated the mortality of individuals with childhood ADHD or subthreshold symptoms associated with perinatal risks who were prospectively followed from birth up to an average age of 46 years. A group with similar perinatal risks but no or low levels of ADHD symptoms was also studied. Causes of death retrieved from a national register were also examined.

Methods

Study design and participants


This study is part of a larger prospective research project following a birth cohort. A total of 1196 infants with predefined perinatal risks born in a single maternity unit in Helsinki, Finland in years 1971–1974 were included in the study. The perinatal risks have been described in detail elsewhere, and included hyperbilirubinemia, birth weight < 2000 g, Apgar score < 7, respiratory distress, maternal diabetes, hypoglycemia, septicemia, or neurological symptoms [23, 24]. Participants with severe disabilities or death before age 5 ($n=202$) were excluded [25].

The cohort was followed at 5 and 9 years of age and underwent comprehensive medical and developmental assessments [23]. Latest in-person follow-up was conducted at age 40 [26]. Participant flow during the follow-up is illustrated in Fig. 1. Comparisons between those who participated in the childhood follow-ups and those lost to follow-up are presented elsewhere [25]. Participants were excluded from the analyses if they had missing birth or childhood information or were evaluated as having a severe disability similar to the original causes for exclusion by age 5. The study group consists of 839 individuals forming three groups: childhood ADHD (cADHD, $n=115$), childhood attention problems (cAP, $n=216$), and no or low levels of attention problems (Non-cAP, $n=508$). Comprehensive data from childhood follow-ups were used to form the groups, comprising questionnaire information from parents, day care, and school, and clinical assessments by a pediatrician, speech therapist, and psychologist. Questionnaires and clinical assessments gathered information on physical and psychological development and included evaluations of hyperactive and inattentive behavior. Participants with ADHD were originally classified as having minimal brain dysfunction, hyperkinetic reaction of childhood, or attention deficit [27, 28]. As ADHD did not exist in the diagnostic system during the childhood follow-ups, the principal researcher (K.M.) later retrospectively classified a total of 122 individuals as having ADHD according to Diagnostic and Statistical Manual of Mental Disorders 4th ed. criteria [29] using childhood data described above, ensuring an onset of symptoms before age 7 and persistence of over 6 months [30]. The cAP group was

Table 1 Previous Studies on Mortality Associated with ADHD

First author (reference)	Year	Origins of Data (country)	Type of Research Design	Total N (ADHD n)	ADHD deceased n	Age of subjects/ Follow-up period	Hazard, mortality or odds ratio (95% CI)	Main outcomes
Chen [7]	2019	National database (Taiwan)	Nationwide population-based cohort study	1 931 860 excluding ADHD cases (275 980)	727	Mean age 9.6, range 4–44 years	AHR 1.07 (1.00–1.17)	The ADHD group had higher overall, suicide, unintentional, and homicide mortality
Sun [8]	2019	National registers (Sweden)	Nationwide cohort study	2 675 615 (86,670)	424	Up to 31 years of age, mean follow-up 11 years	AHR 3.94 (3.51–4.43)	Mortality associated with ADHD was higher in adults than children; cumulative psychiatric comorbidities increased mortality risk
London [9]	2016	Nationally representative survey data (USA)	Prospective sample study	23 352 (unknown)	unknown (2.8% of those diagnosed)	Mean age 47.6 years, followed over 4 years in 2007–2011	AOR 1.78 (1.01–3.12)	Individuals with self-reported ADHD have greater odds of dying after controlling for age
Dalsgaard [6]	2015	National registers (Denmark)	Nationwide cohort study	1 922 248 (32 061)	107	Up to 32 years of age	AMRR 2.07 (1.70–2.50)	ADHD was associated with increased mortality, mainly due to unnatural causes
Barbareis [16]	2013	School and medical records (USA)	Population-based birth cohort study	5718 (367)	7	Mean age at follow-up 27 years, cohort born in 1976–1982	SMR 1.88 (0.83–4.26)	All-cause mortality was not increased in the ADHD group but risk of death from suicide was increased
Klein [4]	2012	Research clinic (USA)	Prospective follow-up study of clinic-referred males	385 (207)	15	Mean age at follow-up 41, subjects enrolled in 1970–1978	Not available	More individuals (all males, 7%) had died by age 41 in the ADHD group compared to a comparison group

CI Confidence interval, AHR Adjusted hazard ratio, AMRR Adjusted mortality rate ratio, AOR Adjusted odds ratio, SMR Standardized mortality ratio



created based on the same childhood data, namely information from informant reports and clinical assessments. Attention problems in the cAP group include both inattentive and hyperactive symptoms and this group represents subthreshold ADHD. For an individual to be classified into the cAP group moderate ADHD symptoms had to be present in at least two settings (i.e., in day care and in one clinical assessment) or severe symptoms in one setting. The diagnostic evaluation for ADHD and forming the childhood attention problems group has been described in more detail elsewhere [26, 30]. The cADHD group had no history of ADHD medication.

Demographical, health and mortality data

Demographical factors related to early health and environment included in the study were gender, birth weight (in grams), Apgar score at 5 min, number of perinatal risks, and childhood socioeconomic status (SES). Perinatal risks were stratified into three classes: 1, 2, and 3 or more risks (range 1–5). Childhood socioeconomic status

(SES) was defined as the highest median status of mother and father recorded in childhood assessments. Four groups based on parents’ occupational level were formed with level one representing the highest status.

Information on time of death was obtained from the Population Register Centre (currently: Digital and Population Data Services Agency), Finland and on the cause of death from Statistics Finland on November 30th, 2019. The deceased were stratified into two age groups, under and over age 30, as previous studies have mainly consisted of individuals up to a maximum average age of 30 (Table 1). Causes of death were classified into four groups: disease, accident, suicide, and self-inflicted disease. Self-inflicted disease comprised deaths in which a harmful lifestyle was considered pivotal, e.g., death with alcoholic liver cirrhosis or acute alcoholic pancreatitis as the sole cause of death. Deaths were also stratified according to natural (disease) or unnatural (accident, suicide, and self-inflicted disease) causes of death. Information on alcohol and

drug use affecting death was collected and recorded separately from the primary cause of death. Positive alcohol or drug use was recorded if the death record included a mention of substance intoxication during events prior to death or alcohol as the main reason for a disease to cause death.

Statistical analysis

Descriptive characteristics of the study group were analyzed with chi square tests for contingency tables and ANOVAs for continuous variables. Bonferroni corrections were applied to pairwise analyses due to multiple comparisons. Effect sizes were calculated as Cramer’s *V* or partial eta squared depending on the analysis. Cox proportional hazard regression models were used to analyze survival in childhood ADHD groups. Time was calculated as years from date of birth to date of death or to the end of follow-up, November 30th, 2019. The unadjusted model included childhood ADHD status. Gender was entered into an adjusted model as a potential covariate. One value for SES was missing and was imputed with the median of the childhood group. Age-specific survival (under and over 30) was analyzed with separate Cox proportional hazard regression models for these age groups adjusted by gender. Cause-specific mortality for natural and unnatural causes of death in different childhood group were likewise analyzed with adjusted Cox proportional hazard regression models with gender as a covariate. Statistical analyses were conducted using IBM SPSS software, version 26.

Results

Table 2 shows descriptive statistics for the entire study group. There were fewer males in the Non-cAP group compared to the other groups. The cADHD group had a lower mean Apgar score than the cAP group and were more likely to have more than one birth risk than the other groups. The cADHD group had more individuals in the lowest childhood SES level and less individuals in the highest childhood SES level than the other groups. Mean age of the cohort excluding the deceased was 46.9 (*SD* = 1.15; range 44–48) and there were no differences in age between the childhood groups (*p* = 0.52).

A total of 38 deaths occurred in the entire cohort during the follow-up between ages 5 and 46. Nearly 10% of the cADHD group had deceased compared to 3%–4% in the other groups (Table 3). Mortality rates in different childhood groups, gender ratios, and mean age at death are presented in Table 3. There were more males in the deceased group (73.7%) than in the alive group (53.7%), $\chi^2(1) = 5.86$, *p* = 0.016. There were no significant differences in birth weight, Apgar score, number of birth risks, or childhood SES between the deceased and alive. Seven deaths had occurred before age 30 in the cADHD group (63.6%), two in the cAP group (28.6%), and four in the Non-cAP group (20.0%).

In the unadjusted Cox regression model childhood ADHD predicted survival (HR 2.53 [1.21, 5.28], *p* = 0.013). The HR remained similar for the cADHD group in the adjusted model (Table 4). Thus, the risk of death by age 46 is twofold in the cADHD group compared to the group with no childhood ADHD or attention problems. Cumulative survival in the childhood groups is illustrated in Fig. 2. Gender was a significant predictor in the adjusted model, with female gender reducing the

Table 2 Cohort characteristics

Characteristic	cADHD (1) <i>n</i> = 115 <i>M</i> ± <i>SD</i> or <i>n</i> (%)	cAP (2) <i>n</i> = 216 <i>M</i> ± <i>SD</i> or <i>n</i> (%)	Non-cAP (3) <i>n</i> = 508 <i>M</i> ± <i>SD</i> or <i>n</i> (%)	<i>F</i> / χ^2 (<i>df</i>)	<i>p</i>	<i>V</i> / η^2	Pairwise comparison
Gender (male)	82 (71.3%)	138 (63.9%)	238 (46.9%)	32.77 (2)	< 0.001	0.20	3 < 1, 2***
Birth weight (gr)	2829.5 ± 915.7	2908.8 ± 831.8	2942.9 ± 886.7	0.80	0.45	0.002	
Apgar score	8.03 ± 2.52	8.70 ± 2.03	8.30 ± 2.31		0.02	0.01	1 < 2*
Number of birth risks				12.28 (4)	0.02	0.09	
1	52 (45.2)	133 (61.6)	308 (60.6)				1 < 2**, 3*
2	43 (37.4)	65 (30.1)	147 (28.9)				
3 or more	20 (17.4)	18 (8.3)	53 (10.4)				1 > 2*
Childhood SES				35.6 (6)	< 0.001	0.15	
Level 1	11 (9.6)	45 (20.8)	113 (22.2)				1 < 2**, 3*
Level 2	26 (22.6)	39 (18.1)	150 (29.5)				2 < 3**
Level 3	59 (51.3)	115 (53.2)	218 (42.9)				2 > 3*
Level 4	19 (16.5)	17 (7.9)	27 (5.3)				1 > 2*, 3***

cADHD Childhood ADHD, cAP Childhood attention problems, Non-cAP No childhood attention problems, SES Socioeconomic status

* *p* < 0.05, ** *p* < 0.01, *** *p* < 0.001

Table 3 Mortality and cause of death in childhood groups

	cADHD (1)	cAP (2)	Non-cAP (3)	<i>p</i>	<i>V</i> / η^2	Pairwise comparison
Characteristic	<i>M</i> ± <i>SD</i> or <i>n</i> (%)	<i>M</i> ± <i>SD</i> or <i>n</i> (%)	<i>M</i> ± <i>SD</i> or <i>n</i> (%)			
Deceased	11 (9.6)	7 (3.2)	20 (3.9)	0.02	0.10	1 > 2,3*
Male (deceased)	9 (81.8)	6 (85.7)	13 (65.0)	0.43	0.21	
Age (deceased)	28.86 ± 9.67	35.33 ± 8.59	37.95 ± 9.79	0.05	0.16	
Cause of death ^a						
Disease	2 (20.0)	2 (28.6)	9 (45.0)			
Accident	3 (30.0)	0 (0)	6 (30.0)			
Suicide	3 (30.0)	3 (42.9)	4 (20.0)			
Self-Inflicted disease	2 (20.0)	2 (28.6)	1 (5.0)			
Alcohol or drug related death	6 (60.0)	3 (42.9)	11 (55.0)	0.08	0.08	

cADHD Childhood ADHD, cAP Childhood attention problems, Non-cAP No childhood attention problems

* *p* < 0.05

^a Total *n* for cause of death = 37, 1 unknown in the cADHD group

Table 4 Cox proportional models predicting mortality risk^a

	Variable	HR [95% CI]	<i>p</i>
All-cause mortality	cADHD	2.15 [1.02, 4.54]	0.04
	cAP	0.73 [0.31, 1.72]	0.47
	Gender (male)	2.21 [1.06, 4.60]	0.04
Mortality before age 30	cADHD	6.20 [1.78, 21.57]	0.004
	cAP	0.98 [0.98, 0.18]	0.98
	Gender (male)	3.51 [0.76, 16.21]	0.11
Mortality for unnatural causes of death	cADHD	2.82 [1.12, 7.12]	0.03
	cAP	0.94 [0.32, 2.72]	0.91
	Gender (male)	2.26 [0.88, 5.78]	0.09

^a All models are adjusted with gender

cADHD Childhood ADHD, cAP Childhood attention problems, Non-cAP No childhood attention problems, HR Hazard ratio, CI Confidence interval

risk of mortality (HR 0.45 [0.22, 0.95], *p* = 0.035). Due to gender being significant in the adjusted model, we added the interaction of gender and childhood group to the model, but this interaction was not significant (*p* = 0.9). Mortality risk was over sixfold in the cADHD group for age-specific mortality before age 30 (Table 4). A similar model for over age 30 did not yield significant results (HR for cADHD = 2.07 [0.79, 9.25], *p* = 0.11).


Cause of death was recorded in 37 out of 38 cases. One cause of death remained unknown in the cADHD group (death abroad resulting in register data not being available). The cause of death was unnatural in 8 out of 10 cases (80%) in the cADHD group, 5 out of 7 cases (71.4%) in the cAP group, and 11 out of 20 cases (55%) in the Non-cAP group. Causes of death in the childhood groups are presented in Table 3. The hazard ratio

for mortality was nearly threefold for unnatural causes of death in the cADHD group compared to the Non-cAP group (Table 4). The cause-specific HR of 1.11 (0.23, 5.32) for natural death in the cADHD group was not significant (*p* = 0.90).

Discussion

Childhood ADHD was associated with increased mortality in this prospective cohort study over 46 years. Deaths in the cADHD group were mostly attributed to unnatural causes and were likely to occur in young adulthood. Childhood subthreshold ADHD symptoms were not associated with increased mortality.

Childhood ADHD was associated with over a twofold increase in mortality risk compared to a group with no childhood ADHD or subthreshold symptoms up to age 46. Our results support findings from large nationwide studies that have found an association between ADHD and increased mortality [6–8]. The twofold increase in mortality is of similar magnitude as in a Danish epidemiological study, where more than double the risk of death for individuals with ADHD was discovered [6]. In contrast, a prospective sample study up to age 27 did not find increased risk of mortality in individuals with ADHD [16]. Compared to another prospective longitudinal study up to age 41, the proportion of deceased (7.2%) equaled over a twofold proportion compared to the comparison group (2.8%), and was similar to the proportion observed in this study (9.6%) [4]. It should be noted that individuals in our study were originally recruited to investigate the effects of perinatal risks on development, and ADHD symptoms were discovered during general assessments. In contrast, the other longitudinal prospective study



described above [4], consists of individuals referred to a medical clinic due to ADHD symptoms, and the prospective sample study used school and medical records to attain ADHD diagnosis [16]. Our results extend the growing evidence of increased mortality associated with ADHD and broaden previous results by showing that increased mortality is also present in a longitudinally followed, non-clinic-referred, and medication-naive cohort with a follow-up of 46 years.

Those in the cADHD group were more likely to die younger than the remaining cohort with over 60% of deaths occurring before age 30. Mortality risk for under age 30 was over sixfold in individuals with childhood ADHD whereas mortality was not increased in the age group of 30 to 46 years. No deaths occurred in the cADHD group in childhood, implying that adolescence and young adulthood might be a period of high risk for those with childhood ADHD. In a Swedish register study of a population of more than 2.6 million, 40 individuals with ADHD had died before the age of 17 [8]. We did not find such an effect in our smaller cohort. Subjects with severe disabilities were excluded from our cohort, which is one possible explanation for no deaths in childhood in our follow-up. Two nationwide studies have examined mortality in different age groups and found the association between increased mortality and ADHD to be higher in adulthood than in childhood [6, 8]. These studies included adults aged 18 to 32 and thus lacked information on mortality rates later in life. This is the first study to imply that mortality risk

associated with childhood ADHD might decrease after young adulthood. Further research is needed to study the effect of age on mortality in ADHD in different age groups in adulthood to identify those at greatest risk of premature death.

The cause-specific mortality risk for unnatural death was higher in the cADHD group compared to the other groups. This risk was over twofold and of similar magnitude as the all-cause mortality risk. Our results support the results of studies that have found greater risk of death due to unnatural causes, especially unintentional injuries and suicides in individuals with ADHD compared to comparison groups [4, 6–8, 16]. Interestingly, the proportion of suicides and accidents as causes of death appeared not to differ between the childhood groups, although we could not statistically analyze this due to a small sample size. Also, because of the small sample size, minor changes in the distribution of causes of death in the childhood groups could result in major changes in the relative proportions. Unnatural causes of death in this study also included diseases in which the main driver was harmful lifestyle. Thus, even though injury-related deaths (accidents and suicides) appeared not to be over-represented in the cADHD group, nearly all deaths in this group could be attributed to behavior increasing the risk of morbidity. Consistent with our finding, ADHD has been associated with reduced estimated life expectancy and reduced healthy life expectancy partly due to common factors associated with increased mortality, such as alcohol and tobacco use [11].

We found no association between subthreshold ADHD symptoms and increased risk of mortality. Prior studies have demonstrated that subthreshold ADHD is linked to high morbidity and functional impairment similar to that of the full disorder, including psychiatric comorbidity and educational and interpersonal dysfunction [19, 21, 22]. Thus, although subthreshold ADHD symptoms pose a risk for adverse functional outcomes, risk of premature death appears not to be elevated. As this is the first study to examine mortality associated with subthreshold levels of ADHD symptoms, further research is needed before more certain conclusions can be drawn.

The cohort in this study consists of individuals with various perinatal risks, which on their own might contribute to mortality risk. Preterm birth has been linked to increased risk of mortality in early to mid-adulthood [31, 32]. A population-based cohort study found low birth weight to increase the risk of mortality in males after age 15 years [33]. Less is known about the association of other perinatal risk factors and adult mortality, but individuals with perinatal complications have been found to exhibit signs of accelerated aging at age 38 years [34]. We did not find birth weight, Apgar score, or the total number of birth risks to differ between the deceased and the remaining cohort. The cADHD group had a lower Apgar score and more birth risks than the other groups, implying that events during birth are likely to contribute to the development of the disorder itself [35].

The main strength of this study is the long follow-up that allowed the examination of mortality associated with ADHD in a prospective longitudinal setting to a later age than any previous studies. Another strength is the investigation of subthreshold ADHD symptoms. To the best of our knowledge, there are no other studies on the mortality associated with non-diagnostic levels of ADHD symptoms. The childhood ADHD group was homogenous due to similarity in perinatal and environmental background (similar perinatal risks, all born in the same hospital and living in urban environments) and due to not being medicated for ADHD. As the ADHD group was not clinic-referred for ADHD, there was no bias related to access to diagnosis.

There are some possible limitations regarding our study. Due to small sample size, we were unable to analyze the effect of all different causes of death in the childhood groups. Information on psychiatric comorbidities was not available and we could not examine comorbidities as possible confounders in mortality. However, in another study of the cohort, we did not find differences between the childhood groups in self-reported alcohol consumption or symptoms of depression and anxiety [26]. Moreover, alcohol and drug use

related to death was similar in the childhood groups, implying that substance misuse was similar in the deceased. Our study cohort consists of individuals with perinatal risks from an era when ADHD medication was not available and generalizations to other populations should be made with caution.

Conclusions

In conclusion, childhood ADHD is associated with a twofold mortality risk by age 46 in a longitudinally followed cohort of individuals with perinatal risks. This risk was higher in young adulthood and deaths were mostly attributed to unnatural causes. Subthreshold levels of childhood ADHD were not associated with increased risk of death. Our results corroborate the morbidity of childhood ADHD during the lifespan. Even though further research is needed, our results suggest that especially young adults with childhood ADHD are at greater risk of premature death, which calls for preventative measures to be aimed at this age group.

Abbreviations

ADHD: Attention deficit hyperactivity disorder; cADHD: Childhood attention deficit hyperactivity disorder; cAP: Childhood attention problems; Non-cAP: No childhood attention problems; SES: Socioeconomic status.

Acknowledgements

Not applicable.

Authors' contributions

N.S. was the main contributor in writing the manuscript and analyzing the data. M.V. contributed to conceptualizing the study and writing the manuscript. L.H. is the principal researcher of the research project and contributed to conceptualizing the study and writing the manuscript. J.L. contributed to conceptualizing the study, analyzing the data, and writing the manuscript. I.J., and E.L. contributed to collecting the data and writing the manuscript. K.M. is the initiator of the original research project and was the principal researcher before L.H. S.L., R.V., and A.T.-H. contributed to writing the manuscript. All authors reviewed the manuscript. The author(s) read and approved the final manuscript.

Funding

The first 30 years of the project were supported by The Academy of Finland, The Signe and Ane Gyllenberg Foundation, The Foundation of Pediatric Research, The Association for Life Insurance Companies, The Traffic Insurer's Centre Finland, and The Rinnekoti Foundation.

The most recent phase has been supported by The Social Insurance Institution of Finland (Kela), The Diabetes Research Foundation, The Juho Vainio Foundation, The Jalmari Ahokas foundation, The Yrjö Jahnsson foundation and The Signe and Ane Gyllenberg foundation. The first author acquired personal grants from the Finnish Cultural Foundation, Alfred Kordelin Foundation and Signe and Ane Gyllenberg Foundation.

Availability of data and materials

The datasets generated and analyzed during the current study are not publicly available due to data sharing restrictions stated by the register owners from whom data was obtained and due to a possibility of individual privacy being compromised but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Infants were originally enrolled with an informed consent by a parent. The ethical review for the follow-up visits at 5, 9, and 16 years of age was done at the Children's Hospital at the Helsinki University Central Hospital. All studies have been conducted in accordance with the Helsinki declaration. Consent has been given at each phase of the follow-up from the parents of all participants in childhood, and from the participants themselves in adulthood. HUS (Helsinki and Uusimaa hospital district) Ethical Review Board, the regional institutional ethics committee for medical research, approved the most recent phase of the project including this study in 2013 (number 147 /13/03/00/13). Permit for data use from Population Registry Centre of Finland was obtained in 2014, 2016, and 2019 (numbers 1665/410/14, 151/410/16, and VRK/5879/2019–3), and from Central Statistical Office of Finland in 2014 and 2019 (numbers TK53-1080–14 and TK53-1690–19). All methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finland. ²Department of Psychiatry, Helsinki University Hospital, Helsinki, Finland. ³Department of Clinical Radiology, Kuopio University Hospital and School of Medicine, Clinical Radiology, University of Eastern Finland, Kuopio, Finland. ⁴Children's Hospital, Helsinki University Hospital, Retired, Helsinki, Finland.

Received: 22 October 2021 Accepted: 27 April 2022

Published online: 09 May 2022

References

- Fayyad J, Sampson NA, Hwang I, Adamowski T, Aguilar-Gaxiola S, Al-Hamzawi A, et al. The descriptive epidemiology of DSM-IV Adult ADHD in the world health organization world mental health surveys. *ADHD Atten Deficit Hyperact Disord*. 2017;9(1):47–65.
- Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA. Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. *J Child Psychol Psychiatry Allied Discip*. 2015;56(3):345–65.
- Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. *BMC Med*. 2012;10:99.
- Klein RG, Mannuzza S, Ramos Olazagasti M a, Roizen Belsky E, Hutchison JA, Lashua-Shriftman E, et al. Clinical and functional outcome of childhood ADHD 33 years later. *Arch Gen Psychiatry*. 2012;69:1295–303.
- Septier M, Stordeur C, Zhang J, Delorme R, Cortese S. Association between suicidal spectrum behaviors and Attention-Deficit/Hyperactivity Disorder: A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2019;103:109–18.
- Dalsgaard S, Ostergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: A nationwide cohort study. *Lancet*. 2015;385(9983):2190–6.
- Chen VCH, Chan HL, Wu SI, Lee M, Lu ML, Liang HY, et al. Attention-deficit/hyperactivity disorder and mortality risk in Taiwan. *JAMA Netw Open*. 2019;2(8):e198714.
- Sun S, Kuja-Halkola R, Faraone SV, D'Onofrio BM, Dalsgaard S, Chang Z, et al. Association of psychiatric comorbidity with the risk of premature death among children and adults with attention-deficit/hyperactivity disorder. *JAMA Psychiat*. 2019;76(11):1141–9.
- London AS, Landes SD. Attention deficit hyperactivity disorder and adult mortality. *Prev Med (Baltim)*. 2016;90:8–10.
- Weye N, Momen NC, Christensen MK, Iburg KM, Dalsgaard S, Laursen TM, et al. Association of specific mental disorders with premature mortality in the Danish population using alternative measurement methods. *JAMA Netw open*. 2020;3(6):e206646.
- Barkley RA, Fischer M. Hyperactive child syndrome and estimated life expectancy at young adult follow-up: the role of ADHD persistence and other potential predictors. *J Atten Disord*. 2019;23(9):907–23.
- Khan A, Faucett J, Morrison S, Brown WA. Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/ hyperactivity disorder participating in psychopharmacology clinical trials. *JAMA Psychiat*. 2013;70(10):1091–9.
- McCarthy S, Cranswick N, Potts L, Taylor E, Wong JCK. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. *Drug Saf*. 2009;32(11):1089–96.
- Chen VCH, Chan HL, Wu SI, Lu ML, Dewey ME, Stewart R, et al. Methylphenidate and mortality in children with attention-deficit hyperactivity disorder: Population-based cohort study. *Br J Psychiatry*. 2022;220(2):64–72.
- Jokela M, Ferrie J, Kivimäki M. Childhood problem behaviors and death by midlife: The British national child development study. *J Am Acad Child Adolesc Psychiatry*. 2009;48(1):19–24.
- Barbareis WJ, Colligan RC, Weaver AL, Voigt RG, Killian JM, Katusic SK. Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study. *Pediatrics*. 2013;131(4):637–44.
- Fitzgerald C, Dalsgaard S, Nordentoft M, Erlangsen A. Suicidal behaviour among persons with attention-deficit hyperactivity disorder. *Br J Psychiatry*. 2019;215(4):615–20.
- Larsson H, Anckarsater H, Råstam M, Chang Z, Lichtenstein P. Childhood attention-deficit hyperactivity disorder as an extreme of a continuous trait: A quantitative genetic study of 8,500 twin pairs. *J Child Psychol Psychiatry Allied Discip*. 2012;53(1):73–80.
- Balázs J, Keresztény Á. Subthreshold attention deficit hyperactivity in children and adolescents: a systematic review. *Eur Child Adolesc Psychiatry*. 2014;23(6):393–408.
- Lecendreux M, Konofal E, Cortese S, Faraone SV. A 4-Year follow-up of attention-deficit/hyperactivity disorder in a population sample. *J Clin Psychiatry*. 2015;76(6):712–9.
- Biederman J, Fitzgerald M, Kirova AM, Woodworth KY, Biederman I, Faraone SV. Further evidence of morbidity and dysfunction associated with subsyndromal ADHD in clinically referred children. *J Clin Psychiatry*. 2018;79(5):17m11870.
- Kirova AM, Kelberman C, Storch B, DiSalvo M, Woodworth KY, Faraone SV, et al. Are subsyndromal manifestations of attention deficit hyperactivity disorder morbid in children? A systematic qualitative review of the literature with meta-analysis. *Psychiatry Res*. 2019;274:75–90.
- Hokkanen L, Launes J, Michelsson K. The Perinatal Adverse events and Special Trends in Cognitive Trajectory (PLASTICITY) - pre-protocol for a prospective longitudinal follow-up cohort study. *F1000Research*. 2013;2:50.
- Michelsson K, Ylinen A, Saarnivaara A, Donner M. Occurrence of risk factors in newborn infants. A study of 22359 consecutive cases. *Ann Clin Res*. 1978;10:334–6.
- Launes J, Hokkanen L, Laasonen M, Tuulio-Henriksson A, Virta M, Lipsanen J, et al. Attrition in a 30-year follow-up of a perinatal birth risk cohort: factors change with age. *PeerJ*. 2014;2:e480.
- Schiaivone N, Virta M, Leppämäki S, Launes J, Vanninen R, Tuulio-Henriksson A, et al. ADHD and subthreshold symptoms in childhood and life outcomes at 40 years in a prospective birth-risk cohort. *Psychiatry Res*. 2019;1(281):112574.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 2nd ed. Washington, DC: American Psychiatric Association; 1968.
- Clements S. Minimal brain dysfunction in children: Terminology and identification (NIND Monograph No. 3). Washington, DC: U.S. Department of Health, Education and Welfare; 1966.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders 4th ed., text rev. (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.

30. Tervo T, Michelsson K, Launes J, Hokkanen L. A prospective 30-year follow-up of ADHD associated with perinatal risks. *J Atten Disord*. 2017;21:799–810.
31. Risnes K, Bilsteen JF, Brown P, Pulakka A, Andersen AMN, Opdahl S, et al. Mortality among young adults born preterm and early term in 4 Nordic nations. *JAMA Netw Open*. 2021;4(1):2032779.
32. Crump C. Preterm birth and mortality in adulthood: a systematic review. *J Perinatol*. 2020;40(6):833–43.
33. Friedlander Y, Paltiel O, Deutsch L, Knaanie A, Massalha S, Tiram E, et al. Birthweight and relationship with infant, child and adult mortality in the Jerusalem perinatal study. *Paediatr Perinat Epidemiol*. 2003;17(4):398–406.
34. Shalev I, Caspi A, Ambler A, Belsky DW, Chapple S, Cohen HJ, et al. Perinatal complications and aging indicators by midlife. *Pediatrics*. 2014;134(5):e1315–23.
35. Thapar A, Cooper M. Attention deficit hyperactivity disorder. *Lancet*. 2016;387(10024):1240–50.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

